Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.
about
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionTyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsRole of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin ToxicitiesThe treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats.Personalized medicine for non-small cell lung cancer: where are we now and where can we go?Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
P2860
Q26783430-28836B26-BDC9-4E9B-9C5F-0DDE9B841630Q28078946-0B3AFE52-491F-45C8-9532-8E1EF291A43DQ41835826-352983C5-35C8-4F72-BA85-2D9DFAE5D04BQ43128868-AE24B675-E022-4867-AEC5-7FAB057648A8Q46566477-6076324A-8664-45FC-A002-05286CFE226AQ47740661-3F85D37B-070C-4166-82B8-1BB3E9C830A4Q47745480-BA4EC13F-A8F2-49B6-890B-389B09527E5BQ49545117-DFB2245E-BD4D-4D94-81A4-818096B38E95Q52591096-B8A96DB7-F252-4617-B7E9-19E2E64666D8Q52653002-CA605DB1-B141-4346-B8EB-D7513DFEB0EAQ54166640-503B53B1-428E-4CA9-826F-223E4025D26CQ57052257-5E81BF52-4D2C-4A10-8C50-F39785FE9DF2
P2860
Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@ast
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@en
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@nl
type
label
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@ast
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@en
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@nl
prefLabel
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@ast
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@en
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@nl
P2860
P356
P1476
Management of Common Toxicitie ...... ncer Therapies with EGFR-TKIs.
@en
P2093
Barbara Melosky
Vera Hirsh
P2860
P356
10.3389/FONC.2014.00238
P577
2014-09-16T00:00:00Z